1. F. Ducray, A. Benouaich-Amiel, A. Idbaih, A. Rousseau, F. Laigle-Donadey, J. Y. Delattre, and M. Sanson. Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. J Neurooncol, 88(2):185-8, 2008. Note: Case ReportsJournal ArticleNetherlands. [WWW] Keyword(s): Aged, Antineoplastic Agents, Alkylating/*therapeutic use, Brain Neoplasms/complications/*drug therapy/genetics/pathology, Chromosome Deletion, Chromosomes, Human, X/genetics, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Dacarbazine/*analogs & derivatives/therapeutic use, Female, Glioblastoma/complications/*drug therapy/genetics/pathology, Humans, Tomography, X-Ray Computed, Tumor Suppressor Proteins/genetics.



2. E. Criniere, G. Kaloshi, F. Laigle-Donadey, J. Lejeune, N. Auger, A. Benouaich-Amiel, S. Everhard, K. Mokhtari, M. Polivka, J. Y. Delattre, K. Hoang-Xuan, J. Thillet, and M. Sanson. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol, 83:173-179, 2007. Note: Journal article. [WWW]



3. G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M. A. Renard, W. Iraqi, A. Idbaih, S. Paris, L. Capelle, H. Duffau, P. Cornu, J. M. Simon, K. Mokhtari, M. Polivka, A. Omuro, A. Carpentier, M. Sanson, J. Y. Delattre, and K. Hoang-Xuan. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology, 68(21):1831-6, 2007. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/administration & dosage, Brain Neoplasms/*drug therapy/*genetics/physiopathology, *Chromosome Deletion, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, DNA Mutational Analysis, Dacarbazine/administration & dosage/*analogs & derivatives, Drug Resistance, Neoplasm/*genetics, Female, Gene Expression Regulation, Neoplastic/drug effects/genetics, Genetic Screening, Genotype, Glioma/*drug therapy/*genetics/physiopathology, Humans, Loss of Heterozygosity/genetics, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy/genetics, Retrospective Studies, Survival Rate, Treatment Outcome.



4. E. Vauleon, N. Auger, A. Benouaich-Amiel, F. Laigle-Donadey, G. Kaloshi, J. Lejeune, J. Y. Delattre, J. Thillet, and M. Sanson. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172(1):33-7, 2007. Note: Journal ArticleUnited States. [WWW]



5. C. Carpentier, F. Laigle-Donadey, Y. Marie, N. Auger, A. Benouaich-Amiel, J. Lejeune, G. Kaloshi, J. Y. Delattre, J. Thillet, and M. Sanson. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology, 67(5):872-4, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Alleles, Chi-Square Distribution, Female, Follow-Up Studies, Gene Frequency, Glioblastoma/*genetics, Humans, Male, Middle Aged, Odds Ratio, *Polymorphism, Genetic, Promoter Regions (Genetics)/*genetics, Prospective Studies, RNA, Messenger/metabolism, Receptor, Epidermal Growth Factor/*genetics, Reverse Transcriptase Polymerase Chain Reaction/methods, Risk Factors, Sp1 Transcription Factor/*metabolism, Survival Analysis.



6. C. Dehais, F. Laigle-Donadey, Y. Marie, M. Kujas, J. Lejeune, A. Benouaich-Amiel, M. Pedretti, M. Polivka, K. H. Xuan, J. Thillet, J. Y. Delattre, and M. Sanson. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer, 107(8):1891-7, 2006. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Aged, 80 and over, Brain Neoplasms/*genetics/mortality, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 10, Chromosomes, Human, Pair 9, Disease-Free Survival, Female, Glioma/*genetics/mortality, Humans, Loss of Heterozygosity, Male, Middle Aged, Molecular Diagnostic Techniques, Prognosis, Receptor, Epidermal Growth Factor/genetics, Survival Analysis, Tumor Suppressor Protein p53/metabolism.



7. S. Everhard, G. Kaloshi, E. Criniere, A. Benouaich-Amiel, J. Lejeune, Y. Marie, M. Sanson, M. Kujas, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, and J. Thillet. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol, 60(6):740-3, 2006. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/pharmacology/therapeutic use, Brain Neoplasms/diagnosis/*drug therapy/genetics, DNA Methylation/*drug effects, DNA Mutational Analysis, Dacarbazine/*analogs & derivatives/pharmacology/therapeutic use, Disease Progression, Female, Genetic Markers/drug effects/genetics, Glioma/diagnosis/*drug therapy/genetics, Humans, Male, Middle Aged, Neoadjuvant Therapy, Predictive Value of Tests, Prognosis, Promoter Regions (Genetics)/*drug effects/genetics, Survival Rate, Tumor Markers, Biological/*genetics, Tumor Suppressor Protein p14ARF/*genetics.



8. C. Houillier, J. Lejeune, A. Benouaich-Amiel, F. Laigle-Donadey, E. Criniere, K. Mokhtari, J. Thillet, J. Y. Delattre, K. Hoang-Xuan, and M. Sanson. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer, 106(10):2218-23, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Base Sequence, Brain Neoplasms/*genetics/*mortality/pathology, Disease Progression, Female, Gene Expression Regulation, Neoplastic, Genes, erbB-1/*genetics, Genetic Markers, Glioblastoma/*genetics/*mortality/pathology, Humans, Male, Middle Aged, Molecular Sequence Data, Multivariate Analysis, Neoplasm Staging, Polymerase Chain Reaction, Probability, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins c-mdm2/*genetics, Registries, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Survival Analysis.



9. M. Sanson, F. Laigle-Donadey, and A. Benouaich-Amiel. Molecular changes in brain tumors: prognostic and therapeutic impact. Curr Opin Oncol, 18(6):623-30, 2006. Note: Journal ArticleUnited States. [WWW]



10. M. Kujas, J. Lejeune, A. Benouaich-Amiel, E. Criniere, F. Laigle-Donadey, Y. Marie, K. Mokhtari, M. Polivka, M. Bernier, F. Chretien, A. Couvelard, L. Capelle, H. Duffau, P. Cornu, P. Broet, J. Thillet, A. F. Carpentier, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol, 58(2):322-6, 2005. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Brain Neoplasms/*genetics/pathology, *Chromosome Deletion, *Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Female, Glioma/*genetics/pathology, Humans, Immunohistochemistry/methods, *Loss of Heterozygosity, Male, Middle Aged, Molecular Biology/methods.



11. F. Laigle-Donadey, A. Benouaich-Amiel, K. Hoang-Xuan, and M. Sanson. [Molecular biology of oligodendroglial tumors]. Neurochirurgie, 51(3-4 Pt 2):260-8, 2005. Note: English AbstractJournal ArticleReviewFrance. [WWW] Keyword(s): Brain Neoplasms/*genetics/*pathology, Chromosome Deletion, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, Cyclin-Dependent Kinase 4/genetics, Gene Expression Regulation, Neoplastic/*genetics, Genes, Tumor Suppressor, Glycoproteins/genetics, Humans, Loss of Heterozygosity/genetics, Molecular Biology/*methods, Oligodendroglioma/*genetics/*pathology, Phenotype, Point Mutation/*genetics, Proto-Oncogene Proteins c-mdm2/genetics.

This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All person copying this information are expected to adhere to the terms and constraints invoked by each author's copyright. In most cases, these works may not be reposted without the explicit permission of the copyright holder.

Les documents contenus dans ces répertoires sont rendus disponibles par les auteurs qui y ont contribué en vue d'assurer la diffusion à temps de travaux savants et techniques sur une base non-commerciale. Les droits de copie et autres droits sont gardés par les auteurs et par les détenteurs du copyright, en dépit du fait qu'ils présentent ici leurs travaux sous forme électronique. Les personnes copiant ces informations doivent adhérer aux termes et contraintes couverts par le copyright de chaque auteur. Ces travaux ne peuvent pas être rendus disponibles ailleurs sans la permission explicite du détenteur du copyright.

This document was translated from BibT_EX by bibtex2html